RocketTickers

Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic process

NYSE:MYOV   None
MYOV: Enzyvant
2021-10-09 20:09:51
Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。